Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
10.1007/s11684-023-1025-7
- Author:
Liming LIAO
1
;
Huilin XU
1
;
Yuhan ZHAO
1
;
Xiaofeng ZHENG
2
Author Information
1. State Key Laboratory of Protein and Plant Gene Research, Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing, 100871, China.
2. State Key Laboratory of Protein and Plant Gene Research, Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing, 100871, China. xiaofengz@pku.edu.cn.
- Publication Type:Review
- Keywords:
CTLA-4;
PD-1;
PD-L1;
combined tumor therapeutic strategies;
immune checkpoint blockade (ICB);
metabolic reprogramming
- MeSH:
Humans;
Antibodies, Monoclonal/pharmacology*;
B7-H1 Antigen/antagonists & inhibitors*;
CTLA-4 Antigen/antagonists & inhibitors*;
Immune Checkpoint Inhibitors/pharmacology*;
Neoplasms/drug therapy*;
Programmed Cell Death 1 Receptor;
Tumor Microenvironment
- From:
Frontiers of Medicine
2023;17(5):805-822
- CountryChina
- Language:English
-
Abstract:
Immunotherapies based on immune checkpoint blockade (ICB) have significantly improved patient outcomes and offered new approaches to cancer therapy over the past decade. To date, immune checkpoint inhibitors (ICIs) of CTLA-4 and PD-1/PD-L1 represent the main class of immunotherapy. Blockade of CTLA-4 and PD-1/PD-L1 has shown remarkable efficacy in several specific types of cancers, however, a large subset of refractory patients presents poor responsiveness to ICB therapy; and the underlying mechanism remains elusive. Recently, numerous studies have revealed that metabolic reprogramming of tumor cells restrains immune responses by remodeling the tumor microenvironment (TME) with various products of metabolism, and combination therapies involving metabolic inhibitors and ICIs provide new approaches to cancer therapy. Nevertheless, a systematic summary is lacking regarding the manner by which different targetable metabolic pathways regulate immune checkpoints to overcome ICI resistance. Here, we demonstrate the generalized mechanism of targeting cancer metabolism at three crucial immune checkpoints (CTLA-4, PD-1, and PD-L1) to influence ICB therapy and propose potential combined immunotherapeutic strategies co-targeting tumor metabolic pathways and immune checkpoints.
